TY - JOUR
T1 - Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
AU - Jacob, Julie
AU - Brié, Heidi
AU - Leys, Anita
AU - Levecq, Laurent
AU - Mergaerts, Filip
AU - Denhaerynck, Kris
AU - Vancayzeele, Stefaan
AU - van Craeyveld, Eline
AU - Abraham, Ivo
AU - Macdonald, Karen
N1 - Publisher Copyright:
© 2017, International Journal of Ophthalmology (c/o Editorial Office). All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2017/1/18
Y1 - 2017/1/18
N2 - AIM: To evaluate the outcomes of ≥6y ranibizumab therapy in neovascular age-related macular degeneration (AMD). ● METHODS: HELIX was a retrospective, observational eff-eciveness study using medical records of patients treated in three clinics in Belgium. Patients had neovascular AMD and were initially treated with intravitreal ranibizumab (0.5 mg) between November 1, 2007 and October 31, 2008, had ≥6y of data available, and were treated on an ongoing, as-needed basis. Outcomes included best-corrected visual acuity (BCVA) and central retinal thickness (CRT). ● RESULTS: The sample consisted of 88 eyes from 69 patients. Mean age was 76.4±6.5y, most patients were female (62.3%). Most eyes (62.5%) were treatment-naive, 33 previously treated eyes had received predominantly other anti-vascular endothelial growth factor agents and verteporfin. Mean baseline BCVA was 57.4±12.7 ETDRS letters and CRT was 292±86 μm. On average, patients received 20.6±11.9 ranibizumab injections over the ≥6y. Intervals between injections were on average 12.7±16.1wk. Mean change in BCVA from baseline to last observation for the sample was less than one letter (-0.9±17.3 letters), with an average loss of -3.2±15.6 letters in previously treated eyes versus a gain of 0.6±18.4 letters in treatment-naïve eyes. When considering a loss of <15 letters over 6y as stabilization of disease, 75.9% of all eyes showed a positive (improvement or stabilization) outcome. Mean change in CRT from baseline to last observation for the sample was -26.9±148.4 μm with the greatest reduction observed in treatment-naive eyes. ● CONCLUSION: This retrospective study of 69 neovascular AMD patients treated for ≥6y with ranibizumab demonstrates long-term visual stabilization. In light of the natural evolution of the disease, these data confirm that ranibizumab is effective long-term under real-world conditions of hetero-geneity of patients, clinicians, and centers.
AB - AIM: To evaluate the outcomes of ≥6y ranibizumab therapy in neovascular age-related macular degeneration (AMD). ● METHODS: HELIX was a retrospective, observational eff-eciveness study using medical records of patients treated in three clinics in Belgium. Patients had neovascular AMD and were initially treated with intravitreal ranibizumab (0.5 mg) between November 1, 2007 and October 31, 2008, had ≥6y of data available, and were treated on an ongoing, as-needed basis. Outcomes included best-corrected visual acuity (BCVA) and central retinal thickness (CRT). ● RESULTS: The sample consisted of 88 eyes from 69 patients. Mean age was 76.4±6.5y, most patients were female (62.3%). Most eyes (62.5%) were treatment-naive, 33 previously treated eyes had received predominantly other anti-vascular endothelial growth factor agents and verteporfin. Mean baseline BCVA was 57.4±12.7 ETDRS letters and CRT was 292±86 μm. On average, patients received 20.6±11.9 ranibizumab injections over the ≥6y. Intervals between injections were on average 12.7±16.1wk. Mean change in BCVA from baseline to last observation for the sample was less than one letter (-0.9±17.3 letters), with an average loss of -3.2±15.6 letters in previously treated eyes versus a gain of 0.6±18.4 letters in treatment-naïve eyes. When considering a loss of <15 letters over 6y as stabilization of disease, 75.9% of all eyes showed a positive (improvement or stabilization) outcome. Mean change in CRT from baseline to last observation for the sample was -26.9±148.4 μm with the greatest reduction observed in treatment-naive eyes. ● CONCLUSION: This retrospective study of 69 neovascular AMD patients treated for ≥6y with ranibizumab demonstrates long-term visual stabilization. In light of the natural evolution of the disease, these data confirm that ranibizumab is effective long-term under real-world conditions of hetero-geneity of patients, clinicians, and centers.
KW - Age-related macular degeneration
KW - Central retinal thickness
KW - Long-term outcome
KW - Optical coherence tomography
KW - Ranibizumab
KW - Visual acuity
KW - Visual function
UR - http://www.scopus.com/inward/record.url?scp=85011068540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011068540&partnerID=8YFLogxK
U2 - 10.18240/ijo.2017.01.14
DO - 10.18240/ijo.2017.01.14
M3 - Article
AN - SCOPUS:85011068540
VL - 10
SP - 81
EP - 90
JO - International Journal of Ophthalmology
JF - International Journal of Ophthalmology
SN - 2222-3959
IS - 1
ER -